CSIMarket
 
22nd Century Group inc   (XXII)
Other Ticker:  
 
    Sector  Consumer Non Cyclical    Industry Tobacco
   Industry Tobacco
   Sector  Consumer Non Cyclical
 
Price: $0.1220 $0.00 -0.894%
Day's High: $0.131 Week Perf: -5.43 %
Day's Low: $ 0.13 30 Day Perf: -22.29 %
Volume (M): 128 52 Wk High: $ 6.89
Volume (M$): $ 17 52 Wk Avg: $0.85
Open: $0.13 52 Wk Low: $0.12



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 20
 Employees 12,700
 Revenues (TTM) (Millions $) 94
 Net Income (TTM) (Millions $) -142
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 6

22nd Century Group Inc

We are a plant biotechnology company focused on technology that allows us to increase or decrease the level of nicotine and other nicotinic alkaloids in tobacco plants and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. Our primary mission is to reduce the harm caused by smoking. We own or exclusively control more than 200 issued patents plus more than 50 pending patent applications.

We are in the process of transitioning from researching and developing our proprietary technology and tobaccos to commercializing our technology and products. According to Euromonitor International annual worldwide tobacco product sales, including cigarettes and smokeless products, are approximately $800 billion, most of which are cigarette sales. If we capture a small fraction of this market, we believe our value will increase tremendously.

We are primarily involved in the following activities:

· The research and development of potentially less harmful or modified risk tobacco products and novel tobacco plant varieties;
· The pursuit of necessary regulatory approvals and clearances from the FDA to market BRAND A in the U.S. as an over-the-counter product labeled as reduced exposure to nicotine as BRAND A has 95% less nicotine than conventional tobacco cigarettes;
· The development of X-22, a prescription-based smoking cessation aid consisting of very low nicotine (“VLN”) cigarettes, and the pursuit of regulatory approvals and clearances from the FDA to market X-22 as a prescription smoking cessation aid;
· The pursuit of necessary regulatory approvals and clearances from the FDA to market BRAND B as a modified risk cigarette with an extremely low tar-to-nicotine ratio;
· The manufacture, marketing and distribution of RED SUN and MAGIC proprietary cigarettes;
· The production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (“NIDA”), a part of the National Institutes of Health (“NIH”);
· The international licensing of our technology, proprietary tobaccos, and trademarks;
· The international sale of our branded proprietary tobaccos;
· The contract manufacturing of third-party branded tobacco products; and
· The research and development in Canada of unique plant varieties of hemp/cannabis, such as (i) plants with low to no amounts of delta-9-tetrahydrocannabinol, or THC, for the legal hemp industry, and (ii) plants with high levels of cannabidiol, or CBD, and other non-THC cannabinoids for the legal medical marijuana markets.

Our prospects depend on our ability to generate and sustain revenues from (i) licensing and/or sale of our proprietary tobacco, technology and products; (ii) domestic and international sales of our brands, including RED SUN and MAGIC; (iii) further development of our potential modified risk tobacco products and our X-22 smoking cessation aid; and (iv) the manufacture of the filtered cigar and cigarette brands of third-parties at our manufacturing facility in North Carolina. Our ability to generate meaningful revenue from our potential modified risk tobacco products in the United States depends on obtaining FDA authorization to market these products as modified risk or reduced exposure; and our ability to generate meaningful revenue in the United States from X-22 depends on FDA approval. If these products are authorized and approved by the FDA, we must still meet the challenges of successful marketing, distribution and consumer acceptance.

We believe our products address unmet needs of smokers; for those who desire to quit, an innovative smoking cessation aid, and for those who are unable or unwilling to quit smoking, cigarettes that may reduce the level of exposure to tobacco toxins and/or nicotine.

We believe our proprietary technology, tobaccos and products will generate multiple significant revenue streams from licensing of our technology and tobacco and from the sales of our products.

Our intellectual property enables us to decrease or increase the level of nicotine and other nicotinic alkaloids in tobacco plants by decreasing or increasing the expression of gene(s) responsible for nicotine production in the tobacco plant using genetic engineering. The basic techniques include, but are not limited to, those that are used in the production of genetically modified (“GM”) varieties of other crops, which are also known as “biotech crops.”

We own or exclusively control more than 200 issued patents plus more than 50 pending patent applications. A “patent family” is a set of patents granted in various countries to protect a single invention. Our patent coverage in the United States and China, two of the most valuable smoking cessation and cigarette markets in the world, consists of 27 issued patents and 21 pending applications and 6 issued patents and 6 pending patent applications, respectively. We have exclusive rights to all uses of the following genes responsible for nicotine content in tobacco plants: NBB, QPT, A622, MPO and several transcription factor genes.

In September 2014, we entered into a Sublicense Agreement with Anandia Laboratories, Inc. (the “Anandia Sublicense”). Under the terms of the Anandia Sublicense, we were granted an exclusive sublicense in the United States and a co-exclusive sublicense in the remainder of the world, excluding Canada, to 1 U.S. patent and 20 patent applications relating to four genes in the cannabis plant that are required for the production of cannabinoids, the active ingredients in the cannabis plant. The Anandia Sublicense continues through the life of the last-to-expire patent, which is expected to be in 2035. As a plant biotechnology company, our entry into the legal hemp/cannabis markets is a natural evolution of our activities in a plant that has important research and commercial value and applications. We intend to engage in research and development activities in Canada to create unique plant varieties of hemp/cannabis, such as (i) plants with low to no amounts of THC for the legal hemp industry, and (ii) plants with high levels of CBD and other non-THC cannabinoids for the legal medical marijuana markets.

We own various registered trademarks in the United States. We also have exclusive plant variety rights in the United States (plant variety protection certificates are issued by the U.S. Department of Agriculture (“PVP”)) and Canada. A PVP certificate prevents anyone other than the owner/licensee from planting, propagating, selling, importing and exporting a plant variety for twenty (20) years in the U.S. and generally for twenty (20) years in other member countries of the International Union for the Protection of New Varieties of Plants, known as UPOV, an international treaty concerning plant breeders’ rights. There are currently more than 70 countries that are members of UPOV.



   Company Address: 500 Seneca Street Buffalo 14204 NY
   Company Phone Number: 270-1523   Stock Exchange / Ticker: NASDAQ XXII
   


Customers Net Income grew by XXII's Customers Net Profit Margin grew to

76.64 %

29.79 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BTI        0.87% 
MO        3.39% 
PM        0.7% 
VGR   -2.88%    
VPRB   -2.88%    
• View Complete Report
   



Management Changes

Unlocking Shareholder Value and Paving the Way for a Healthier Future: 22nd Century Group's Transformative Journey in Tobacco Assets

Published Wed, Nov 29 2023 12:07 PM UTC

Unlocking Shareholder Value and Paving the Way for a Healthier Future: 22nd Century Group's Transformative Journey
In a strategic move aimed at unlocking shareholder value and driving innovation in the tobacco industry, 22nd Century Group, Inc. (Nasdaq: XXII) has appointed Larry Firestone as Chairman and CEO. With his extensive experience in turnarounds, Firestone is set...

Product Service News

22nd Century Group Inc Takes Strategic Step Towards Streamlining Operations and Improving Financial Performance

Published Mon, Nov 27 2023 9:44 PM UTC


22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise and Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash Requirements
In a strategic move, 22nd Century Group Inc has announced that it has entered into an agreement to sell its hemp/cannabis franchise. This sale is expected to have a positive impact on the...

22nd Century Group Inc

Diminishing Returns Plague 22nd Century Group Inc. as Orders Decline in Financial Time-Frame Closing September 30, 2023

The stock market can be a rollercoaster ride of ups and downs, and it's important to stay informed about the latest news and updates from the companies you invest in. In that regard, 22nd Century Group Inc has recently reported its financial results for the third quarter ending September 30, 2023, and provided key insights into its business trajectory.
In this financial time-frame, 22nd Century Group Inc faced some challenges with lower orders, resulting in diminishing revenue and greater losses. The company reported a loss per share of $-3.48, which is an increase from the previous year. Furthermore, revenue fell by -8.11% to $17.81 million compared to the same quarter last year.
Although these numbers may seem concerning, it is vital to look at the bigger picture. In the previous financial period, the company realized a revenue of $23.43 million with a bottom line of $-1.40 per share, demonstrating growth and improvement over time.
While the net loss of $-73.284 million for the third quarter may be higher than the previous year, it is essential to consider the various factors at play. The buildup in inventories is worth noting, as the level of inventories and supplies has increased to $16.0 million compared to the preceding quarter and the corresponding quarter a year ago.

Shares

22nd Century Group's Transformative Public Offering: Paving the Way for a Healthier Future

Published Mon, Oct 16 2023 8:05 PM UTC



In an exciting development, 22nd Century Group, Inc. (Nasdaq: XXII) - a pioneering biotechnology company renowned for its cutting-edge advancements in reduced nicotine tobacco, hemp/cannabis, and hops plant technologies - has announced its intention to offer a best efforts public offering. The proceeds from this offering will enable the Company to further advance i...

22nd Century Group Inc

22nd Century Group Inc. Achieves Record-Breaking 175.905% Revenue Growth in First Quarter of 2023

22nd Century Group Inc., a leading biotechnology company focused on reducing the harms caused by smoking, recently released its financial results for the time-frame ending March 31, 2023. The company reported a 175.905% growth in revenue, which reached $21.96 million compared to $7.96 million in the same period last year. However, the revenue sequentially fell by -28.644% from $30.78 million.
The company's earnings per share (EPS) improved from $-0.10 per share from the previous reporting season to $-0.08 per share. Additionally, the net loss per share decreased from $-0.09 a year ago. Despite these improvements, the company incurred a net loss of $-18.182 million this year, up from $-13.965 million last year.






 

22nd Century Group Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com